Urinary calprotectin: Can
it be the best tumor marker in detecting urothelial carcinoma of the bladder?
Although, there have been many serum and urine biomarkers described for
diagnosis and follow-up of bladder cancer, none of these could have eliminated
the need for cystoscopy and cytology. The present study investigates whether
calprotectin may serve as a urinary biomarker in the detection of urothelial
and Methods: Urine and tissue calprotectin levels of patients with primary bladder
cancer (52 patients, study group) and benign prostate hyperplasia (30 patients,
control group) were measured and compared. Tissue samples were obtained with
transurethral resection and measurements were performed using ELISA test.
The mean urinary calprotectin concentrations were significantly higher in
patients with bladder cancer (432.7±456.6 ng/mL) compared to controls
(50.5±71.6 ng/mL) (p